Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
IDEAYA and Roche Collaboration | Lucid Diligence Brief
IDEAYA and Roche Test IDE892 plus RG6505 in MTAP-Deleted RAS-Mutant PDAC…
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI Partnership in CNS Oncology
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI partnership raises…
Lucid Diligence Brief: Stipple Bio $100 million Series A
Lucid Diligence Brief: Stipple Bio $100 million Series A Professional audiences…
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership…
Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from Synnovation
Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from…
Oncology Today—February 2, 2026
This weekly update in oncology covers regulatory actions, clinical progress,…
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
The defining idea of 2025 was execution at scale—more patients pulled into…
SABCS 2025 Preview: Key Breast Cancer Highlights to Watch
Get ready for SABCS25 with LucidQuest’s concise preview of the sessions…
Lucid Diligence Brief: Abbott to acquire Exact Sciences
Lucid Diligence Brief: Abbott to acquire Exact Sciences Professional audiences…
Lucid Diligence Brief: Guardant Health and Zephyr AI partnership
Lucid Diligence Brief: Guardant Health and Zephyr AI partnership Professional…